The first problem is that of the optimal volume allocation in procurement. The choice of this problem was motivated by a study whose objective was to support decision-making at two procurement organizations for the procurement of Depot Medroxyprogesterone Acetate (DMPA), an injectable contraceptive. At the time of this study, only one supplier that had undergone the costly and lengthy process of WHO pre-qualification was available to these organizations. However, a new entrant supplier was expected to receive WHO qualification within the next year, thus becoming a viable second source for DMPA procurement. When deciding how to allocate the procurement volume between the two suppliers, the buyers had to consider the impact on price as well as risk. Higher allocations to one supplier yield lower prices but expose a buyer to higher supply risks, while an even allocation will result in lower supply risk but also reduce competitive pressure, resulting in higher prices. Our research investigates this single- versus dual-sourcing problem and quantifies in one model the impact of the procurement volume on competition and risk. To support decision-makers, we develop a mathematical framework that accounts for the characteristics of donor-funded global health markets and models the effects of an entrant on purchasing costs and supply risks. Our in-depth analysis provides insights into how the optimal allocation decision is affected by various parameters and explores the trade-off between competition and supply risk. For example, we find that, even if the entrant supplier introduces longer leads times and a higher default risk, the buyer still benefits from dual sourcing. However, these risk-diversification benefits depend heavily on the entrant’s in-country registration: If the buyer can ship the entrant’s product to only a selected number of countries, the buyer does not benefit from dual sourcing as much as it would if entrant’s product could be shipped to all supplied countries. We show that the buyer should be interested in qualifying the entrant’s product in countries with high demand first. In the second problem we explore a new tendering mechanism called the postponement tender, which can be useful when buyers in the global health industry want to contract new generics suppliers with uncertain product quality. The mechanism allows a buyer to postpone part of the procurement volume’s allocation so the buyer can learn about the unknown quality before allocating the remaining volume to the best supplier in terms of both price and quality. We develop a mathematical model to capture the decision-maker’s trade-offs in setting the right split between the initial volume and the postponed volume. Our analysis shows that a buyer can benefit from this mechanism more than it can from a single-sourcing format, as it can decrease the risk of receiving poor quality (in terms of product quality and logistics performance) and even increase competitive pressure between the suppliers, thereby lowering the purchasing costs. By considering market parameters like the buyer’s size, the suppliers’ value (difference between quality and cost), quality uncertainty, and minimum order volumes, we derive optimal sourcing strategies for various market structures and explore how competition is affected by the buyer’s learning about the suppliers’ quality through the initial volume. The third problem considers the repeated procurement problem of pharmacies in Kenya that have multi-product inventories. Coordinating orders allows pharmacies to achieve lower procurement prices by using the quantity discounts manufacturers offer and sharing fixed ordering costs, such as logistics costs. However, coordinating and optimizing orders for multiple products is complex and costly. To solve the coordinated procurement problem, also known as the Joint Replenishment Problem (JRP) with quantity discounts, a novel, data-driven inventory policy using sample-average approximation is proposed. The inventory policy is developed based on renewal theory and is evaluated using real-world sales data from Kenyan pharmacies. Multiple benchmarks are used to evaluate the performance of the approach. First, it is compared to the theoretically optimal policy --- that is, a dynamic-programming policy --- in the single-product setting without quantity discounts to show that the proposed policy results in comparable inventory costs. Second, the policy is evaluated for the original multi-product setting with quantity discounts and compared to ex-post optimal costs. The evaluation shows that the policy’s performance in the multi-product setting is similar to its performance in the single-product setting (with respect to ex-post optimal costs), suggesting that the proposed policy offers a promising, data-driven solution to these types of multi-product inventory problems. / Der erste Teil, welcher eine gemeinsame Arbeit mit Dr. Alexander Rothkopf und Prof. Dr. Richard Pibernik entstanden ist, ist durch eine Studie motiviert, die Entscheidungsträgern zweier Einkaufsorganisationen beim Einkauf von Depot Medroxyprogesterone Acetate (DMPA), einem länger wirkenden Verhütungsmittel, unterstützen sollte. Zum Zeitpunkt der Studie stand den Organisationen nur ein qualifizierter Lieferant zur Verfügung. Ein zweiter Zulieferer stand kurz vor der Zulassung. Ziel der Arbeit war es den Mehrwert des neuen Lieferanten zu quantifizieren und die optimale Aufteilung der Bestellmengen zwischen beiden Lieferanten zu ermitteln. Hierbei spielt die Abwägung von Preisen (getrieben durch den Wettbewerb zwischen beiden Lieferanten) und Risiko (getrieben durch unsichere Lieferzeiten und Ausfallwahrscheinlichkeiten) eine entscheidende Rolle. In unserer Arbeit zeigen wir wie sich die optimale Aufteilung anhand diverser Parameter, wie Lieferzuverlässigkeit, Kosten und Kapazität, verändert, und untersuchen die Abwägungsentscheidung zwischen Wettbewerb und Risiken. Im zweiten Teil, der ebenfalls eine gemeinsame Arbeit mit Dr. Alexander Rothkopf und Prof. Dr. Richard Pibernik ist, untersuchen wir einen innovativen Einkaufsmechanismus den wir "Postponement Tender" nennen. Das zugrundeliegende Problem ist das eines Einkäufers, welcher mit der unsicheren Qualität eines neuen Lieferanten konfrontiert ist, und der daraus resultierenden Allokationsentscheidung zwischen bestehendem und neuen Lieferanten. Anstatt alles auf einmal zu vergeben, kann der Einkäufer auch zuerst einen Teil des Volumens an beide Lieferanten vergeben, um die unsichere Qualität des neuen Lieferanten besser einzuschätzen. Nachdem die Lieferanten die ersten Volumina geliefert haben kann der Einkäufer die Qualität der Lieferanten besser beurteilen und kauft dann die nachgelagerte Menge vom besseren Lieferanten. Da die Lieferanten bereits zu Beginn Preise festlegen müssen, kann der Einkäufer durch diesen Mechanismus sowohl durch verbesserten Wettbewerb profitieren als auch von einem niedrigeren Qualitätsrisiko, da er dabei etwas über die Qualität der Lieferanten lernt. Wir zeigen in einer detaillierten Analyse wie, abhängig von Einkaufs- und Wettbewerbssituation, die Aufteilung zwischen dem ersten und dem zweiten Teil erfolgen sollte und unter welchen Bedingungen der "Postponement Tender" besser als eine klassische Einzelquellenbeschaffung ist. Der dritte Teil ist durch den Business Case kenianischer Apotheken motiviert: diese können durch die Koordination von Bestellungen niedrigere Einkaufspreise aufgrund von Mengenrabatten bei Lieferanten erzielen sowie fixe Bestellkosten wie Logistikkosten teilen. Aufgrund einer Vielzahl von Produkten ist diese Koordination allerdings sehr komplex und mit einem hohen Aufwand sowie Kosten verbunden. Um diese Hürde zu überwinden entwickle ich eine neue, datengetriebene Bestellpolitik für mehrperiodische Bestandsmanagementprobleme mit mehreren Produkten und Skaleneffekten in fixen sowie variablen Bestellkosten. Die entwickelte Politik beruht auf den Prinzipien von Erneuerungstheorie und Sample Average Approximation. Des Weiteren analysiere ich die Performance dieser Politik anhand realer Daten aus dem zugrundeliegenden Business Case. In einer ersten Auswertung zeigt sich, dass die resultierenden Kosten nah an denen der theoretisch optimalen Bestellpolitik liegen. Weiter wird gezeigt, dass sich das Verhältnis zu ex-post optimalen Kosten in Szenarien, in denen es keine theoretisch optimale Bestellpolitik gibt (mehrere Produkte und Mengenrabatte) im selben Rahmen befindet wie in Szenarien mit optimaler Bestellpolitik. Insgesamt zeigt der entwickelte Ansatz viel Potential für die Lösung komplexer Bestandsplanungsprobleme.

In this edition, we take a closer look at compliance in the healthcare industry, and focus on questions arising from the fast-growing healthcare compliance system. Our first set of articles explicitly deals with that issue.

In this edition, we take a closer look at compliance in the healthcare industry, and focus on questions arising from the fast-growing healthcare compliance system. Our first setof articles explicitly deals with that issue.

The meaning of Corporate Governance is all values and principles guiding or regulating good and responsible business management. Clearly defined roles and responsibilities for managing compliance, risks and checks is the prerequisite for the latter. For that reason, a compliance management system was set up at the University Hospital Frankfurt in 2015.

This piece describes the journey of a student on a LawWithoutWalls ("LWOW") team that was charged with helping a large multinational defense firm, Lockheed Martin, solve this problem. This piece is not designed to teach the reader about supply chain management; instead, it will exemplify through a real-life experience how tough it is to teach people who are not compliance experts about the field’s complexities and, further, explore the difficulty in developing creative, practicable solutions to compliance problems.

German companies or German-based subsidiaries of international businesses may become subject of, or otherwise involved in, investigations by German or foreign regulatory or law enforcement authorities. In the context of such investigations, it is not unusual for the concerned company to face informal requests from German or foreign regulatory and law enforcement authorities for voluntary cooperation. Oftentimes, such requests focus on the transfer of electronic data for investigatory purposes, and such data typically relate, in whole or in part, to individuals (e.g. employees, suppliers and customers). In these and other cases, compliance of German companies or German-based subsidiaries with informal requests from regulatory and law enforcement authorities may itself entail a compliance risk or even constitute a breach by the corporate entity of the German data protection laws resulting in criminal prosecution, administrative sanctions, or damage claims and other actions by third party individuals. This article outlines the scope of application of the German Federal Data Protection Act, introduces the applicable statutory provisions, and discusses the relevant considerations in the context of an informal request by a regulatory or law enforcement authority for voluntary cooperation in the context of global investigations, in particular where a German-based entity faces requests from authorities abroad.

In light of the demanding requirements inherent to the operation of a university hospital, a multitude of compliance risks are entailed in the medical care, training, and research entail which such institutions are engaged in. If such risks materialize, the public will notice, which will substantially tarnish not only the public’s confidence in the proper functioning and the integrity of the impacted hospital, but ultimately, the whole German health care system. In examining the structural and requisite prevention protocols, three risk groups can be distinguished. The Düsseldorf University Hospital provides a leading example in the area of compliance management.

Conflicts of interest (COI) in healthcare have increasingly gained attention in the lay press as well as among healthcare professionals. COIs increase the risk of undue influence on professional decision making and may have far-reaching consequences in healthcare. Therefore, it is essential to develop strategies to deal with such risk situations in order to prevent negative outcomes for patients and the health care system. This article describes recent research on COIs in Germany as well as initiatives aiming at more transparency and better management of COIs in Germany.

The Munich Compliance Talk entitled "Legal Privilege – What is its use actually about?" took place on April 26th, 2016 at the Literaturhaus Munich. At this event, which has been organized together by the Deutschen AnwaltSpiegel – Gruppe and Recommind, compliance professionals, namely lawyers, employees of in-house legal departments, compliance officers and compliance managers have been present. The conference program included impulsive lectures by the experts Dr. Burkhard Schmitt1 (Vice President, Head of EMEIA Compliance at Fujitsu, Munich) and Patrick Späth2, LL.M. (Counsel of WilmerHale in Berlin). Emphasis was – among other things - placed on the legal framework of legal privilege. Moreover the focus was on the company's point of view, thus the question, how to deal with legal privilege in the company.

Computer Science approaches (software, database, management systems) are powerful tools to boost research. Here they are applied to metabolic modelling in infections as well as health care management. Starting from a comparative analysis this thesis shows own steps and examples towards improvement in metabolic modelling software and health data management. In section 2, new experimental data on metabolites and enzymes induce high interest in metabolic modelling including metabolic flux calculations. Data analysis of metabolites, calculation of metabolic fluxes, pathways and their condition-specific strengths is now possible by an advantageous combination of specific software. How can available software for metabolic modelling be improved from a computational point of view? A number of available and well established software solutions are first discussed individually. This includes information on software origin, capabilities, development and used methodology. Performance information is obtained for the compared software using provided example data sets. A feature based comparison shows limitations and advantages of the compared software for specific tasks in metabolic modeling. Often found limitations include third party software dependence, no comprehensive database management and no standard format for data input and output. Graphical visualization can be improved for complex data visualization and at the web based graphical interface. Other areas for development are platform independency, product line architecture, data standardization, open source movement and new methodologies. The comparison shows clearly space for further software application development including steps towards an optimal user friendly graphical user interface, platform independence, database management system and third party independence especially in the case of desktop applications. The found limitations are not limited to the software compared and are of course also actively tackled in some of the most recent developments. Other improvements should aim at generality and standard data input formats, improved visualization of not only the input data set but also analyzed results. We hope, with the implementation of these suggestions, metabolic software applications will become more professional, cheap, reliable and attractive for the user. Nevertheless, keeping these inherent limitations in mind, we are confident that the tools compared can be recommended for metabolic modeling for instance to model metabolic fluxes in bacteria or metabolic data analysis and studies in infection biology. ... / Informatik Ansätze (Software, Datenbank, Management-Systeme) sind wichtige Werkzeuge für die Forschung in der Biologie. Ausgehend von einer vergleichenden Analyse zeigt diese Arbeit eigene Schritte und Beispiele zur Verbesserung von metabolischer Modellierungs-Software und Gesundheit Datenmanagementsystemen auf. Neue experimentelle Daten über Metaboliten und Enzyme führen zu hohem Interesse an metabolischen Modellierungen einschließlich Stoffwechselflusses Berechnungen. In Kapitel 2 zeigen wir, das die Datenanalyse von Metaboliten, die Berechnung der Stoffflüsse und Wege sowie die spezifischen Softwarestärken nur durch eine vorteilhafte Kombination voll ausgeschöpft werden. Wie kann Software zur metabolischen Modellierung von einer informatischen Sicht her verbessert werden? Eine Anzahl von verfügbaren und gut etablierten Softwareansätzen wird zunächst einzeln diskutiert. Dazu gehören Informationen über Software-Herkunft, Fähigkeiten, Entwicklung und verwendeten Methodik einschließlich Testdatensätzen und Modellen. Ein Vergleich zeigt, merkmalsbasierte Einschränkungen und Vorteile der verglichenen Software für spezifische Aufgaben in der metabolischen Modellierung. Häufige Einschränkungen der verglichenen Software sind ihre Abhängigkeit von Drittanbietern, kein umfassendes Datenbank-Management und kein Standard-Format für Dateneingabe und -ausgabe. Die grafische Visualisierung für komplexe Visualisierungen von Daten und die Web-basierte grafische Benutzeroberfläche kann oft noch verbessert werden. Andere Bereiche für weitere Entwicklung sind Plattformunabhängigkeit, Produktlinien-Architektur, Daten-Standardisierung, die Open-Source-Bewegung und neue Algorithmen und Methoden. Der Vergleich zeigt deutlich Möglichkeiten für weitere Entwicklung von Softwareanwendungen auf, einschließlich Schritten in Richtung einer optimalen, benutzerfreundlichen grafischen Benutzeroberfläche, Plattform-Unabhängigkeit, Datenbank-Management-System und Unabhängigkeit von weiterer software, vor allem im Falle von Desktop-Anwendungen. Die gefundenen Einschränkungen sind von allgemeiner Bedeutung für bioinformatische Modellierungssoftware einschließlich jüngster Entwicklungen. Weitere Verbesserungen betreffen standardisierte Formate und eine, verbesserte Visualisierung von Eingabedatensatz und analysierten Ergebnissen. Wir hoffen, dass mit der Umsetzung dieser Vorschläge metabolische Software-Anwendungen professioneller werden, billiger, zuverlässiger und attraktiver für den Anwender. Trotz dieser inhärenten Einschränkungen im Hinterkopf sind wir zuversichtlich und ...